ACU401 / Acumen Pharma - LARVOL DELTA

EBD bispecific program (ACU301/ACU401) achieved up to ~40x higher brain exposure in NHPs and supports subcutaneous dosing (TradingView) - "IND targeted mid-2027."

IND • Preclinical • Alzheimer's Disease

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery (EBD) Development Candidates for the Treatment of Alzheimer’s Disease (The Manila Times) - "ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen’s option under its license agreement with JCR Pharmaceuticals...Acumen’s EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format; Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027."

IND • Pipeline update • Alzheimer's Disease